Xylocor Therapeutics Inc.
- Address
- 1200 Liberty Ridge Drive
Sponsor Overview
Specializations
Coronary artery disease and angina
Research activity centers on chronic angina and refractory angina linked to obstructive coronary artery disease, with attention to persistent symptoms despite standard cardiovascular care.
- Chronic angina
- Refractory angina
- Obstructive coronary artery disease
The clinical focus includes symptom relief and reduction of ischemic manifestations in patients with limited treatment options.
Ischemic burden and myocardial perfusion
Trials examine residual ischemic burden and stress-induced perfusion abnormalities in participants with coronary disease, including those at risk for incomplete surgical revascularization.
- Residual ischemic burden
- Myocardial perfusion
- Incomplete revascularization
Interest extends to imaging-based assessment of ischemia and its relationship to ongoing cardiac symptoms.
Left ventricular dysfunction and cardiac function
Another focus is left ventricular dysfunction associated with coronary artery disease, particularly in patients undergoing coronary artery bypass grafting who may remain incompletely revascularized.
- Left ventricular dysfunction
- Cardiac contractile function
- Coronary artery bypass grafting
This area reflects interest in preserving or improving ventricular performance in ischemic heart disease.
Cardiac imaging and exercise-based assessment
Clinical evaluation incorporates stress imaging, cardiovascular magnetic resonance, positron emission tomography, and treadmill exercise testing to characterize ischemia and functional limitation in coronary disease.
- Cardiovascular magnetic resonance
- Positron emission tomography
- Graded treadmill testing
These domains support measurement of ischemic severity, exercise capacity, and cardiac performance in symptomatic patients.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A 26-Week (with 26 Week Extension) Randomized, Multi-Center, Double-Blind Phase 2 Study to Evaluate the Efficacy and Safety of XC001 Gene Therapy as an Adjunct to Coronary Artery Bypass Graft Surgery for Patients with Symptomatic Coronary Artery Disease with Left Ventricular Dysfunction at Risk for Incomplete Revascularization |  Germany Hungary Poland The Netherlands | Not Recruiting |
| Phase 2b Randomized Study of Encoberminogene Rezmadenovec in Refractory Angina Due to Coronary Artery Disease with Flurpiridaz F 18 and 13N-Ammonia |  Belgium Germany Hungary Poland The Netherlands | Not Yet Recruiting |
Data & Insights
This sponsor works with 4 molecules, of which 1 is not being studied by other sponsors.
This sponsor has worked with 37 sites across their trial portfolio.
Therapeutic Focus
- 1.Cardiovascular Diseases2 trials359 other sponsors
Partnered Research Centres
37 centres- Address
- Ul. Aleje Raclawickie 23, 20-049 Lublin
- Address
- Deltalaan 1, 8800 Roeselare
- Address
- Aleja Armii Krajowej 101, 43-316 Bielsko-Biala
- Address
- Ul. Topolowa 16, 32-500 Chrzanow
- Address
- Ul. Edukacji 102, 43-100 Tychy
- Address
- Meibergdreef 9, 1105 AZ Amsterdam
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Xylocor Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.